Thursday broker round-up UPDATE
16th Jan 2014 08:59
Aberdeen Asset Management: Canaccord Genuity cuts target price from 586p to 540p, while its buy recommendation remains unchanged. Anglo American: UBS ups target price from 1500p to 1580p upgrading from neutral to buy. Antofagasta: Investec reduces target price from 716p to 685p maintaining a sell
Read moreTuesday broker round-up UPDATE
12th Nov 2013 09:20
Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu
Read moreTuesday broker round-up UPDATE
10th Sep 2013 08:17
African Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell. Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral. As
Read moreCraneware profit slips as revenue holds up
10th Sep 2013 07:18
Edinburgh based software company Craneware said full year revenue was marginally ahead of last year, but profit was hit after it failed to secure a major contract. The group, which provides revenue assessing software to US hospitals, said revenue increased 1% to $41.5m for the year ended June 30th
Read moreCraneware earnings to be below market forecasts
26th Jun 2013 08:02
Craneware warned that revenues and earnings for the year will be in line or marginally ahead of last year but below current market forecasts. The Scotland-based firm, which provides revenue assessing software to US hospitals, said it continues to see increased levels of sales activity and conversio
Read moreWednesday broker round-up UPDATE
26th Jun 2013 07:30
ACM Shipping Group: Espirito Santo increases target price from 150p to 185p keeping a buy recommendation. Afren: Canaccord Genuity moves target price from 210p to 220p and keeps a buy recommendation. Aggreko: Deutsche Bank cuts target price from 2250p to 2100p, while its buy recommendation remains
Read more3i Chief adds 2.5m shares to stake
27th Feb 2013 16:12
Simon Borrows, the Chief Executive of 3i Group, the international investor focused on mid-market private equity, this week bought 2.5m 3i shares in three tranches. The three tranches consisted of 550,000 shares purchased at 308.22p, 374,809 at 312.38p, and 1.6m at 305.84p. Altogether the purchases
Read moreWednesday broker round-up UPDATE
27th Feb 2013 08:11
: Panmure Gordon reduces target price from 2159p to 1742p and reiterates its hold recommendation. Antofagasta: JP Morgan cuts target price from 1485p to 1400p, while retaining its overweight rating. Barclays: Numis raises target price from 351p to 400p and upgrades to buy. BT Group: UBS moves tar
Read moreRevenue growth continues at Craneware
21st Jan 2013 07:13
US healthcare software developer Craneware said first half trading has been positive as increased levels of sales start to contribute to revenue growth. The group, which provides monitoring and automated revenue systems, said it expects to report revenue growth to $20.1m, up from $18.8m in the same
Read moreMonday broker round-up UPDATE
21st Jan 2013 07:02
Abbey Protection: Numis increases target price from 90p to 120p and upgrades to add. Admiral: Goldman Sachs upgrades to buy from neutral, raising its price target to 1500p from 1160p before. Aggreko: Bank of America lowers target price from 2700p to 1950p and downgrades to neutral. Anglo Americ
Read moreMonday broker round-up UPDATE
19th Nov 2012 07:34
Aquarius Platinum: Nomura raises target price from 35p to 95p and upgrades from neutral to buy. Associated British Foods; Societe Generale upgrades to buy from hold. Atkins: Jefferies reduces target price from 850p to 800p, buy recommendation reiterated. Aveva: Panmure Gordon reduces target price
Read moreTwo City of London directors dispose of beneficial interests
6th Sep 2012 17:10
Two directors of emerging markets-focused investment group City of London disposed of beneficial interests they have in the company on Wednesday, just two days after the firm's full-year results revealed a large decline in funds under management (FuM). Non-executive director David Cardale and Finan
Read moreWednesday broker round-up
5th Sep 2012 09:20
AMEC: Nomura retains buy rating and 1,240p target. Ashtead: UBS ups target from 340p to 375p, buy rating unchanged. ASOS: Oriel Securities upgrades to buy; BarCap upgrades to overweight, target lifted rom 1,800p to 2,400p. BP: Investec keeps buy rating and 460p target. BT Group: JPMorgan Cazenov
Read moreCraneware revenues up on US healthcare cost pressures
4th Sep 2012 09:52
UK-listed but US-focused healthcare software provider Craneware is benefiting from the cost pressures on American hospitals. The company, which provides monitoring and automated revenue systems, has reported revenues of $41.1m in the 12 months to the end of June, a rise of 8% on the prior year. Ad
Read moreCraneware sees lower than expected full year earnings
2nd Jul 2012 07:42
US healthcare software developer Craneware said adjusted EBITDA will be below current market expectations for the year. The board expects to report revenue for the year in the region of $41m compared to $38.1m the year before. Adjusted EBITDA rose 15% from the previous year's figure of $10.1m. Thi
Read more